Pharmacology

Browse 61 topics in pharmacology.

61 results

Alfentanil and Sufentanil Pharmacology

Alfentanil and sufentanil are synthetic 4-anilidopiperidine opioid agonists derived from fentanyl, sharing its characteristic phenylpiperidine structure but with distinct pharmacokinetic profiles that determine their...

Intravenous Opioid Analgesics1 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Atracurium and Cisatracurium: Pharmacology

Atracurium is a benzylisoquinolinium non-depolarizing neuromuscular blocker with unique Hofmann elimination (chemical degradation at physiological pH and temperature) and ester hydrolysis by plasma cholinesterases....

Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written

Atracurium Pharmacology

Atracurium besylate is an intermediate-acting, non-depolarizing benzylisoquinolinium neuromuscular blocking agent (NMBA) characterised by organ-independent elimination through Hofmann elimination (spontaneous chemical...

Benzylisoquinolinium Neuromuscular Blocking Agents31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Atropine Pharmacology

Atropine is a naturally occurring tropane alkaloid and the prototypical competitive muscarinic acetylcholine receptor antagonist. As a tertiary amine with a pKa of 9.7, it crosses the blood-brain barrier and produces...

Muscarinic Antagonists31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Beta-Blockers Pharmacology

Beta-adrenergic receptor antagonists (beta-blockers) competitively inhibit catecholamine binding at beta-adrenoceptors, producing negative chronotropy (reduced heart rate), negative inotropy (reduced contractility),...

Cardiovascular Pharmacology1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Bupivacaine

Bupivacaine is a potent, long-acting amide local anaesthetic widely used for neuraxial blocks (epidural, spinal), peripheral nerve blocks, and labour analgesia. Structure: Amide local anaesthetic (pipecoloxylidide),...

Local Anaesthetic Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Calcium Channel Blockers Pharmacology

Calcium channel blockers (CCBs) inhibit voltage-gated L-type calcium channels, reducing calcium influx into cardiac and vascular smooth muscle cells. Classification is based on chemical structure : dihydropyridines...

Cardiovascular Drugs1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Clonidine Pharmacology

Clonidine is a selective alpha-2 (α2) adrenergic receptor agonist with central sympatholytic, sedative, and analgesic properties that make it valuable in perioperative medicine. It is an imidazoline derivative that...

Alpha-2 Adrenergic Receptor Agonists3 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+2

Clozapine

Clozapine is the prototypical atypical (second-generation) antipsychotic and remains the most effective pharmacological ... MRCPsych exam preparation.

Psychopharmacology9 Jan 2025Peer reviewed
Psychiatry
Clinical Pharmacology
High evidence
MRCPsych

Corticosteroids Pharmacology

Corticosteroids are synthetic analogues of endogenous cortisol with varying ratios of glucocorticoid (anti-inflammatory, metabolic) to mineralocorticoid (sodium retention) activity. In anaesthesia, they are used for...

Corticosteroids1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Desflurane: Pharmacology and Clinical Use

Desflurane is a fluorinated methyl ethyl ether with lowest blood/gas partition coefficient (0.42), providing most rapid emergence of volatile agents. Physical properties : High vapor pressure (669 mmHg at 20°C),...

Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written

Dexmedetomidine Pharmacology

Dexmedetomidine is a highly selective alpha-2 adrenoceptor agonist (α2:α1 ratio 1620:1 ) used for sedation in intensive care and procedural settings. It produces "cooperative sedation" via inhibition of noradrenergic...

Alpha-2 Agonists1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Dexmedetomidine: Pharmacology and Clinical Use

Dexmedetomidine is a highly selective alpha-2 adrenergic agonist with sedative, anxiolytic, and analgesic properties. Mechanism : Acts on alpha-2A receptors in locus coeruleus (sedation), spinal cord (analgesia), and...

Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Diazepam: Pharmacology and Clinical Applications in Anaesthesia

Diazepam is a long-acting benzodiazepine that acts as a positive allosteric modulator at the GABA-A receptor, producing anxiolysis, sedation, amnesia, and anticonvulsant effects. Its clinical utility is limited in...

3 Feb 2026
ANZCA Primary
Pharmacology
+1

Direct Oral Anticoagulants (DOACs) Pharmacology

Direct Oral Anticoagulants (DOACs), also termed Non-vitamin K Antagonist Oral Anticoagulants (NOACs), represent a pharmacological revolution in anticoagulation therapy, offering predictable pharmacokinetics, fixed...

Anticoagulants1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Drug-Induced Liver Injury

Pattern classification is fundamental: hepatocellular (ALT-predominant), cholestatic (alkaline phosphatase-predominant), or mixed, determined by the R-ratio: (ALT/ULN) ÷ (ALP/ULN). R ≥5 indicates hepatocellular...

Hepatotoxicity9 Jan 2026Peer reviewed
Gastroenterology
Clinical Pharmacology
High evidence

Ephedrine Pharmacology

Ephedrine is a non-catecholamine sympathomimetic amine with both direct and indirect actions at alpha and beta adrenergic receptors. It is a naturally occurring alkaloid found in plants of the Ephedra species....

Mixed-acting Sympathomimetics3 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+2

Etomidate Pharmacology

Etomidate is an imidazole-derived intravenous anaesthetic agent distinguished by its remarkable haemodynamic stability, making it the induction agent of choice for patients with cardiovascular compromise or...

Intravenous Anaesthetic Agents31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Fentanyl

Fentanyl is a synthetic phenylpiperidine opioid agonist with 100× potency of morphine and rapid onset (1-2 minutes IV), making it ideal for intraoperative analgesia and balanced anaesthesia. Mechanism: Selective...

Opioid Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Flumazenil Pharmacology

Flumazenil is a competitive benzodiazepine antagonist at the GABA-A receptor benzodiazepine binding site. Chemically classified as an imidazobenzodiazepine, it reverses the sedative, anxiolytic, and amnestic effects...

GABA-A Receptor Modulators1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Gabapentinoids Pharmacology (Gabapentin and Pregabalin)

Gabapentinoids (gabapentin and pregabalin) are anticonvulsant medications that bind to the α2δ subunit of voltage-gated calcium channels (VGCCs) , reducing presynaptic calcium influx and neurotransmitter release...

Adjuvant Analgesics1 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Gentamicin Prescribing in Adults

Gentamicin is a bactericidal aminoglycoside antibiotic with potent activity against aerobic Gram-negative bacteria, including Pseudomonas aeruginosa . It is characterized by:

Antimicrobial Stewardship5 Jan 2026Peer reviewed
Clinical Pharmacology
Infectious Diseases
High evidence
+1

Glyceryl Trinitrate (GTN) Pharmacology

Glyceryl trinitrate (GTN), also known as nitroglycerin, is an organic nitrate vasodilator that has been used clinically for over 150 years for the treatment of angina pectoris and heart failure. It is a triester of...

Nitrate Vasodilators3 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+2

Glycopyrrolate

Glycopyrrolate is a quaternary ammonium anticholinergic agent with peripheral muscarinic receptor antagonism, used primarily to counteract muscarinic side effects of anticholinesterases during neuromuscular blockade...

Anticholinergics2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Glycopyrrolate Pharmacology

Glycopyrrolate (glycopyrronium bromide) is a synthetic quaternary ammonium anticholinergic agent that acts as a competitive muscarinic receptor antagonist at M1, M2, and M3 receptor subtypes. Its quaternary ammonium...

Muscarinic Antagonists31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Hydralazine: Direct Vasodilator Pharmacology and Clinical Use

Hydralazine is a direct-acting arterial vasodilator that relaxes vascular smooth muscle through unclear mechanisms, possibly involving interference with calcium influx and activation of potassium channels. It produces...

3 Feb 2026
ANZCA Primary
Pharmacology
+1

Isoflurane Pharmacology

Isoflurane (1-chloro-2,2,2-trifluoroethyl difluoromethyl ether) is a halogenated methyl ethyl ether volatile anaesthetic agent introduced in 1981 that remains widely used globally for maintenance of general...

Volatile Agents1 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Ketamine

Ketamine is a phencyclidine (PCP) derivative dissociative anaesthetic producing analgesia, amnesia, and unconsciousness while preserving airway reflexes and cardiovascular stability. Mechanism: Non-competitive...

IV Anaesthetics2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Ketamine Pharmacology

Ketamine is a phencyclidine derivative dissociative anaesthetic that exists as two stereoisomers: S(+)-ketamine and R(-)-ketamine. The S(+)-enantiomer demonstrates 3-4 times greater analgesic potency and 1.5-2 times...

Intravenous Anaesthetic Agents31 Jan 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Lignocaine (Lidocaine)

Lignocaine (lidocaine) is the prototypical amide local anaesthetic, widely used for infiltration, nerve blocks, spinal and epidural anaesthesia, intravenous regional anaesthesia (Bier's block), and as an...

Local Anaesthetic Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Local Anaesthetics

Local anaesthetics (LAs) block nerve conduction by inhibiting voltage-gated sodium channels (VGSC) in neuronal membranes, preventing action potential generation and propagation. Classification: Esters (procaine,...

Local Anaesthetic Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Magnesium Pharmacology

Magnesium (Mg²⁺) is the fourth most abundant cation in the body and second most abundant intracellular cation, with critical roles in over 300 enzymatic reactions, neuromuscular transmission, and cardiac...

Electrolytes/Minerals1 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Malignant Hyperthermia: Recognition and Management

Malignant hyperthermia (MH) is a pharmacogenetic disorder triggered by volatile anaesthetics (sevoflurane, isoflurane, desflurane, halothane) and suxamethonium . Pathophysiology : Ryanodine receptor (RYR1) or DHPR...

Resuscitation-Critical2 Feb 2026
ANZCA Final
Crisis Management
High evidence
ANZCA Final Written
+1

Metaraminol Pharmacology

Metaraminol is a synthetic sympathomimetic amine used primarily as a vasopressor for the management of intraoperative hypotension, particularly during spinal anaesthesia for caesarean section. It acts through both...

Sympathomimetics31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Midazolam Pharmacology

Midazolam is a water-soluble imidazobenzodiazepine that acts as a positive allosteric modulator of GABA-A receptors at the alpha-gamma subunit interface, enhancing chloride conductance to produce anxiolysis, amnesia,...

Sedatives/Hypnotics1 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Midazolam: Pharmacology and Clinical Use

Midazolam is a short-acting benzodiazepine with anxiolytic, amnestic, sedative-hypnotic, and muscle relaxant properties. Mechanism : Positive allosteric modulation of GABA-A receptors (increases chloride conductance,...

Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written

Morphine

Morphine is the prototypical phenanthrene μ-opioid receptor (MOR) agonist, the gold standard against which other opioids are compared. Structure: Phenanthrene backbone (5-ring structure), tertiary amine, two hydroxyl...

Opioid Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Morphine Pharmacology

Morphine is the prototypical natural opioid analgesic derived from the phenanthrene alkaloid class, acting as a full agonist at mu (μ), kappa (κ), and delta (δ) opioid receptors with primary clinical effects mediated...

Analgesic Pharmacology1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Neostigmine

Neostigmine is a reversible acetylcholinesterase inhibitor used to reverse non-depolarizing neuromuscular blockade (NMB) by increasing acetylcholine (ACh) concentration at the neuromuscular junction, overcoming...

Anticholinesterases2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Neostigmine and Anticholinesterase Pharmacology

Neostigmine is a quaternary ammonium anticholinesterase agent that reversibly inhibits acetylcholinesterase through carbamylation, increasing acetylcholine concentration at the neuromuscular junction to reverse...

Autonomic Pharmacology1 Feb 2026
ANZCA Primary
Pharmacology
A evidence
ANZCA Primary Examination
+1

Nitrous Oxide Pharmacology

Nitrous oxide (N2O) is a colourless, sweet-smelling inhalational anaesthetic agent with unique physicochemical properties that distinguish it from volatile anaesthetics. Key ANZCA Primary exam points include:...

General Anaesthesia1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Nitrous Oxide Pharmacology

Nitrous oxide (N2O) is a colorless, odorless, non-irritating gas and the only inorganic compound used as a general anaesthetic. It is the weakest inhalational anaesthetic with a MAC (minimum alveolar concentration) of...

Inhalational Anaesthetic Agents3 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Noradrenaline (Norepinephrine) Pharmacology

Noradrenaline (norepinephrine) is an endogenous catecholamine and the primary neurotransmitter of the sympathetic nervous system, acting predominantly at alpha-1 adrenoceptors (potent vasoconstriction) with additional...

Cardiovascular Pharmacology1 Feb 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Ondansetron Pharmacology

Ondansetron is a selective 5-HT₃ (serotonin type 3) receptor antagonist used primarily for the prevention and treatment of postoperative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV)....

5-HT3 Receptor Antagonists31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Oxycodone and Tramadol Pharmacology

Oxycodone and tramadol represent two distinct approaches to opioid analgesia with fundamentally different pharmacological profiles essential for ANZCA Primary examination. Oxycodone is a semi-synthetic opioid derived...

Opioids1 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Phenylephrine Pharmacology

Phenylephrine is a synthetic, non-catecholamine sympathomimetic amine that acts as a selective alpha-1 adrenergic receptor agonist with minimal beta-adrenergic activity. Unlike catecholamines (epinephrine,...

Cardiovascular Pharmacology31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Phenylephrine: Pharmacology and Clinical Use

Phenylephrine is a direct-acting α-1 adrenergic receptor agonist with potent vasoconstrictor effects and no β-activity. Mechanism : Stimulates postsynaptic α-1 receptors on vascular smooth muscle → vasoconstriction →...

Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Postoperative Nausea and Vomiting Prophylaxis

Postoperative nausea and vomiting (PONV) affects 20-30% of surgical patients and 70-80% of high-risk patients, significantly impacting patient satisfaction, delaying discharge, and increasing costs. Risk...

General Clinical2 Feb 2026
ANZCA Final
Perioperative Medicine
High evidence
ANZCA Final Written
+1

Propofol

Propofol (2,6-diisopropylphenol) is the most commonly used intravenous anaesthetic agent for induction and maintenance of general anaesthesia and sedation in ICU. Structure: Simple phenol derivative with two isopropyl...

IV Anaesthetics2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Propofol Pharmacology

Propofol (2,6-diisopropylphenol) is a phenol derivative intravenous anaesthetic that acts primarily as a positive allosteric modulator of GABA A receptors, particularly at the beta-subunit, increasing chloride...

Intravenous Anaesthetic Agents31 Jan 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Remifentanil Pharmacology

Remifentanil is a synthetic ultra-short-acting mu-opioid agonist distinguished by its unique ester linkage that allows rapid hydrolysis by non-specific tissue and plasma esterases, resulting in organ-independent...

Intravenous Opioid Analgesics31 Jan 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Rocuronium

Rocuronium is an aminosteroid non-depolarizing neuromuscular blocking agent (NMBA) with rapid onset (60-90 seconds) making it suitable for rapid sequence intubation (RSI) when succinylcholine contraindicated....

Muscle Relaxants2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Sevoflurane

Sevoflurane is a fluorinated ether inhalational anaesthetic with blood:gas partition coefficient 0.65 (low solubility), enabling rapid induction and emergence compared to isoflurane (1.4) and halothane (2.4). MAC...

Inhalational Agents2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Sodium Nitroprusside Pharmacology

Sodium nitroprusside (SNP) is a potent, rapid-acting, direct-acting vasodilator that produces arteriolar and venous dilation through non-specific release of nitric oxide (NO). It is a complex inorganic compound...

Direct-Acting Vasodilators3 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+2

Sugammadex Pharmacology

Sugammadex is a modified gamma-cyclodextrin designed specifically to encapsulate and inactivate steroidal neuromuscular blocking agents (rocuronium vecuronium pancuronium), providing rapid and complete reversal of...

Neuromuscular Block Reversal Agents31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Suxamethonium (Succinylcholine)

Suxamethonium (succinylcholine) is the only depolarizing neuromuscular blocker in clinical use, providing rapid onset (30-60 seconds) and ultra-short duration (5-10 minutes) ideal for rapid sequence intubation....

Muscle Relaxants2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Thiopentone (Thiopental) Pharmacology

Thiopentone (thiopental sodium) is a thiobarbiturate intravenous anaesthetic agent that was the original gold standard for anaesthetic induction for over 50 years before propofol's dominance. Its structure features a...

Intravenous Induction Agents1 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Total Intravenous Anaesthesia (TIVA) and Target Controlled Infusion (TCI)

Total intravenous anaesthesia (TIVA) provides complete anaesthesia without volatile agents using continuous IV drug infusions, offering advantages in PONV reduction (50% lower than volatiles), neurosurgery (reduced...

General Clinical2 Feb 2026
ANZCA Final
Pharmacology
High evidence
ANZCA Final Written
+1

Tranexamic Acid Pharmacology

Tranexamic acid (TXA) is a synthetic lysine analogue antifibrinolytic agent that competitively inhibits plasminogen activation by blocking lysine-binding sites, thereby preventing fibrin clot degradation. TXA is...

Antifibrinolytic Agents31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Vasopressin and Analogues Pharmacology

Vasopressin (arginine vasopressin, AVP), also known as antidiuretic hormone (ADH), is an endogenous nonapeptide synthesised in the hypothalamic supraoptic and paraventricular nuclei and released from the posterior...

Cardiovascular Pharmacology31 Jan 2025
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written
+1

Vecuronium: Pharmacology and Clinical Use

Vecuronium is an intermediate-acting aminosteroid non-depolarizing neuromuscular blocker . Structure : Steroid nucleus with quaternary ammonium groups (bisquaternary). Mechanism : Competitive antagonist at nicotinic...

Pharmacology2 Feb 2026
ANZCA Primary
Pharmacology
High evidence
ANZCA Primary Written